Overview

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

The objective of the trial is to compare the lung function profile of once daily treatment with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung function profile of twice daily treatment with fluticasone propionate+salmeterol FDC [250/50µg and 500/50µg] delivered by the Accuhaler® after 6 weeks of treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Fluticasone
Olodaterol
Salmeterol Xinafoate
Tiotropium Bromide
Xhance